8.89
-0.14(-1.55%)
Currency In USD
| Previous Close | 9.03 |
| Open | 8.67 |
| Day High | 9.64 |
| Day Low | 8.67 |
| 52-Week High | 19.2 |
| 52-Week Low | 2.69 |
| Volume | 11,299 |
| Average Volume | 92,892 |
| Market Cap | 23.79M |
| PE | -0.34 |
| EPS | -25.97 |
| Moving Average 50 Days | 6.13 |
| Moving Average 200 Days | 6.48 |
| Change | -0.14 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $37.23 as of October 24, 2025 at a share price of $8.89. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $67.78 as of October 24, 2025 at a share price of $8.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
GlobeNewswire Inc.
Oct 16, 2025 12:05 PM GMT
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc.
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced